Middle East & Africa Cell and Gene Therapy Market

The Middle East & Africa cell and gene therapy market was valued at US$ 129.17 million in 2023 and is projected to reach US$ 469.34 million by 2031; it is estimated to record a CAGR of 17.5% from 2023 to 2031.

Automation of Cell and Gene Therapy Manufacturing Services Boosts Middle East & Africa Cell and Gene Therapy Market

Incorporating automation in cell and gene therapy manufacturing can lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices designed to boost the automation of most sequential unit operations for a CAR-T process within a single system. With the rise in demand for cell and gene therapies, the production of cell and gene therapy products has shifted from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to commercialization has propelled the demand for automation in commercial manufacturing. Further, government agencies are adopting automation in the manufacturing of cell therapies to increase national production capabilities. Thus, automation of cell and gene therapy manufacturing services is expected to bring new trends in the Middle East & Africa cell and gene therapy market in the coming years.

Middle East & Africa Cell and Gene Therapy Market Overview

South Africa is a developing nation. The proper implementation of a cell therapy program in South Africa can result in the reduction of the high disease burden in the country; however, the cost of cell and gene therapy restricts South African patients' access to these therapies. Despite being technologically more advanced than other African nations, gene therapy manufacturing is still not widely available in South Africa. The most problematic aspects are the lack of funding, human resources, and awareness about therapy. Although the South African government has made efforts to support the biotechnology industry, cell therapy has not received enough attention. Moreover, the scientific and medical community is highly innovative and focused on cell and gene therapy.

Middle East & Africa Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Cell and Gene Therapy Strategic Insights

Strategic insights for the Middle East & Africa Cell and Gene Therapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Cell and Gene Therapy Report Scope

Middle East & Africa Cell and Gene Therapy Regional Insights

The geographic scope of the Middle East & Africa Cell and Gene Therapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Cell and Gene Therapy Market Segmentation 

The Middle East & Africa cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Middle East & Africa cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Middle East & Africa cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Middle East & Africa cell and gene therapy market is bifurcated into pre commercial/ R and D manufacturing and commercial scale manufacturing. The pre commercial/ R and D manufacturing segment held a larger market share in 2023.

Based on end user, the Middle East & Africa cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Middle East & Africa cell and gene therapy market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Middle East & Africa cell and gene therapy market.